Two
stories in the past two weeks, one on
the therapeutic cloning of human stem
cells,1
and the other on the successful replication of DNA containing two
new, non-naturally occurring synthetic DNA bases in a cell2
have prompted me to turn to the subject
of bioethics. I have been studying and writing about
biotechnology since 1984
and for quite a while
people would conflate biotechnology with bioethics. When I would tell
people that my area of law was focused
on biotechnology, I would frequently get
the response,
"like designer babies?" I would respond, "No,
that's a bioethics issue, and I rarely do anything ethical." My
joking response was intended to emphasize the distinction between
biotechnology, which is simply the use of modern molecular biology as
a tool in a variety of areas, from bioethics, which is the effort to
analyze issues concerning human life and health in ethical terms. In
the 1980's and much of the '90's,
my response was true. The
biotechnology industry was focused on healthcare innovation and faced
numerous issues concerning intellectual property rights and federal
regulation. Very few, if any, of the
issues faced by the developing
biotechnology industry raised new or difficult ethical issues.
Companies were (and are) trying to develop human therapeutics
and diagnostics and the ethical issues were much the same as had
faced the pharmaceutical and medical device industry for decades:
informed consent;
ensuring that clinical trials provided a sufficient potential for
good to justify human experimentation;
and,
providing access to lifesaving drugs in less developed regions of the
world. Then,
in 1998, James Thompson and others at the University of Wisconsin
reported that they had successfully isolated and
cultured human embryonic stem cells.3
With that step,
some of what biotechnology researchers and companies were attempting
to do became embroiled in ethical controversy. Soon
afterwards, in 2001, the Human Genome
Project announced the completion of the first draft of the complete
human genome. Issues of genetic testing and genetic discrimination,
which had been simmering for some time, became much more imminent. I
could no longer make my joke, as embryonic stem cells and
genetic testing were no joking matter
and could not be ignored.
As
bioethics moved center stage in the discussion of biotechnology I
had to pay attention to the debate and formulate my own views on
these issues. I participated in a symposium on From
Chance to Choice: Genetics and Justice
at
the University of San Diego. At that symposium I was privileged to
have an opportunity to disagree
with Francis Collins, then the director of the Human Genome Project
and now the Director of the NIH,
about whether or not genetic discrimination in the workplace could
ever be ethically justified (he said no and I said yes).
In my first publication on a bioethics topic, A
Rawlsian Approach to Solving the Problem of Genetic Discrimination
in Toxic Workplaces,4
I
expanded
on that argument and asserted that the
ethical issues surrounding genetic testing could best be addressed
by the application of the rich philosophical framework provided by
John Rawls in his Theory
of Justice (1971).
In later forays into bioethics, for example, in relation to the
issue of longevity research,5
I have continued to adhere to what I believe is a straightforward
and relatively fundamentalist (to use the word in its pure,
non-religious sense of sticking to basic principles) approach to
various issues. In Western society, there are really only two basic
secular (that is to say non-revelation-based)
approaches to deciding what is right or good: a utilitarian approach
and a
Kantian
approach.6
Let
me briefly elaborate on my claim about utilitarian and Kantian
approaches being the two fundamental,
non-revelation-based
ways of analyzing ethical issues in the U.S. and other Western
societies. First, I am obviously leaving aside the various religious
traditions and their moral or ethical frameworks. As they are
"revelation-based" and disagree with one another on many
important bioethical questions, there is no possibility of coming to
an agreement about questions such as the use of in-vitro
fertilization, egg-donation, stem cell research, or other issues,
because the "truth"
of the Catholic or Jewish or Muslim
answers
to these issues can never be demonstrated to adherents of
other traditions without divine intercession into the debate. In the
absence of such a miracle, as a practical matter we can only decide
on the goodness or rightness of an answer to a problem based on
whether
or not
it does more overall good than harm (utilitarian) or whether or
not it
is in conformity with the principle of respecting others as
autonomous individuals entitled to pursue their own ends, rather than
using others for our ends (Kantian). It
is
not
always obvious what the utilitarian or Kantian answer to a question
is, however,
we
are more or less limited to those alternative approaches along with a
number of variations of them.
With
that as prologue, what can we say about the latest stem cell
development, which is the announcement
that two separate
teams
of scientists had succeeded in "cloning" by replacing the
nuclear DNA of an embryonic stem cell with the nuclear DNA from an
adult cell? For
this discussion of ethics in biomedical research, I will evaluate the
ethical issues raised by the work of one of those teams,
a group
of
scientists led by Dieter Egli of the New York Stem Cell Foundation
Research Institute.
Egli's group
replaced the embryonic cell's nucleus with the DNA from a cell of a
32-year-old
woman with diabetes, and then succeeded in guiding the resulting
cloned cell to differentiate into insulin-producing
cells. This research clearly has the potential to lead to
breakthrough treatments for diabetes as well as many other human
diseases. From a utilitarian perspective, there is the destruction
of an embryo originally created for in vitro fertilization by an
infertile couple, who no longer wish to use that embryo for
conception, weighed against the possible benefit to mature humans
suffering from a serious disease that is not completely treatable
with existing therapies. This
research and future research along these lines is clearly ethical
from a utilitarian perspective. It is equally ethical
from
a Kantian perspective,
provided
that the
relevant autonomous persons,
in this case the
man and woman whose egg and sperm created the embryo
and
the diabetic woman whose cells were used as the "donor"
DNA, were fully informed of the nature of the research and freely
consented to that research without any coercion or duress of
any kind. Note that whatever value or rights might be ascribed to
the embryo by particular religious traditions, it cannot be said to
have a "will" or "autonomy" in a Kantian sense.
The donation of the embryo to science is very much the "parents'"
autonomous choice, no less than would be the decision
of other parents
to allow
organ donation from their
brain-dead infant
for
medical research.
The
second news story that created headlines was about researchers at
Scripps Research Institute in La Jolla creating two new DNA building
blocks which were successfully incorporated into and replicated by a
cell. This
synthetic
DNA issue is even easier to analyze
than the stem cell question.
While synthetic biology is often met with alarmed expressions
of concern about
scientists "playing God," that concern can only be
interpreted either as meaning that the accuser believes the
scientists performing such research are transgressing some natural
law boundary
that
is revelation-derived (and therefore out of bounds in this
discussion) or that such research poses unknowable risks of
Frankensteinian consequences. This second concern, that this
research, like that of the fictional Dr. Frankenstein, risks
unleashing terrible consequences raises the question of the ethics of
research that poses uncertain risks. This is primarily a
utilitarian problem, not a Kantian one, for no one would seriously
suggest that the cells involved have any kind of Kantian right to
determine whether or not they are the object of synthetic biology
research.
From
a utilitarian perspective some
questions
about uncertain risks
can be very difficult to resolve, however,
that is not the case here. While experiments in counteracting global
warming by spraying the upper atmosphere with sulfur dioxide might
well be very difficult to assess within a utilitarian framework
because of the uncertainties of climate science,7
the synthetic DNA experiment is not at all difficult to assess from a
research safety perspective. The synthetic DNA was self-limiting, as
the cell could not produce more of it beyond that which it was "fed"
by the researchers. It could not create pathogenicity in the cell by
any conceivable mechanism. It is very nifty biochemistry. It may
transgress a number of religions norms. It is not, however, a
serious bioethical dilemma.
1
Monya
Baker, Cell
lines made by two separate teams could boost the prospects of
patient-specific therapies,
April
28, 2014, available at
http://www.nature.com/news/stem-cells-made-by-cloning-adult-humans-1.15107
2
Andrew
Pollack, Scientists
Add Letters to DNA’s Alphabet, Raising Hope and Fear,
NY Times, May 8, 2014 at A1.
3
James A. Thomson,
Joseph Itskovitz-Eldor, Sander S. Shapiro, Michelle A.
Waknitz,
Jennifer J.
Swiergiel,
Vivienne S. Marshall, Jeffrey M. Jones,
Embryonic Stem Cell Lines
Derived from Human Blastocysts,
282:5391 SCIENCE
1145-1147
(November 6, 1998).
4
39 San
Diego L. Rev. 747 (2002).
If you really want to know how I justified genetic discrimination in
the workplace (to exclude those hypersensitive to workplace toxins)
you will just have to read the article.
5
Longevity Research
and Bioethics, 23
Biotechnology L. Rep. 542 (2004)
6
Rawls'
contribution was to demonstrate the possibility of a synthesis of
those two approaches using a contractarian framework to construct
the good or just society.
Rawls reasoned that the just society would
maximize overall welfare (a
utilitarian
virtue)
with fundamental respect for all, most
significantly by limiting the extent to which those
most disadvantaged by nature or fortune
suffered
as a consequence of their disadvantage (Kantian
equality and respect for all).
For a further, much more lengthy introduction to Rawls, see Leif
Wenar, "John Rawls", The
Stanford Encyclopedia of Philosophy (Winter
2013 Edition), Edward N. Zalta (ed.),
available at
http://plato.stanford.edu/archives/win2013/entries/rawls/.
7See
Michael Specter, The Climate Fixers,
The NEW YORKER, May 14, 2012 available at
http://www.newyorker.com/reporting/2012/05/14/120514fa_fact_specter?currentPage=all
No comments:
Post a Comment